Literature DB >> 3609111

Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard.

M Beerahee, M R Wilkins, D B Jack, D G Beevers, M J Kendall.   

Abstract

Variation in plasma nifedipine concentrations have been reported and one study has suggested the existence of a subpopulation of poor metabolisers of this drug. We have studied the variability of 12 h plasma nifedipine concentrations in 64 hypertensive patients on long-term nifedipine Retard 20 mg twice daily. A slightly skewed unimodal distribution with a modal concentration of 15 to 30 ng/ml was obtained. No relationship between 12-h plasma levels and debrisoquine hydroxylation phenotype was found.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609111     DOI: 10.1007/bf00543967

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Treatment of angina pectoris with nifedipine.

Authors:  J R Idle; P S Sever
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

Review 2.  Drug metabolism in the elderly: confounding of age, smoking, and ethanol effects.

Authors:  E M Sellers; R C Frecker; M K Romach
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

3.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

Authors:  C H Kleinbloesem; P van Brummelen; H Faber; M Danhof; N P Vermeulen; D D Breimer
Journal:  Biochem Pharmacol       Date:  1984-11-15       Impact factor: 5.858

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.

Authors:  M J Kendall; D B Jack; S J Laugher; J Lobo; S Rolf Smith
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

  5 in total
  2 in total

Review 1.  Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.

Authors:  Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.